French Memory Support System: A Pilot Study

Bruyère Health Research Institute.10 enrolled

Overview

The purpose of this study is to develop a linguistically and culturally appropriate adaptation of the Memory Support System (MSS), an evidence-based intervention to train persons with mild cognitive impairment (MCI) to complete personal goals and instrumental activities of daily living independently. The study will involve development of the associated manual, training and patient forms, and outcome measures, and pilot testing of the intervention in a group of French-speaking individuals with MCI and their care partners

At enrollment, participants with MCI and their care partners will complete French measures evaluating cognitive and functional status. Participants and partners will also complete French measures of treatment adherence, instrumental activities of daily living, self-efficacy for memory, quality of life, mood, anxiety, and caregiver burden at baseline, treatment end, and 8-week follow-up. Participants will complete the MSS training consisting of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after initial assessment.

Study Type

INTERVENTIONAL

Allocation

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

Conditions

Mild Cognitive Impairment

Interventions

Memory Support SystemBEHAVIORAL

The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment.

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * diagnosis of single or multi-domain MCI * Clinical Dementia Rating global (CDR) score of ≤ 0.5 * Dementia Rating Scale-Second edition score of ≥ 115 * available contact with a care partner ≥ 2 times weekly * absence or stable intake of nootropic(s) for ≥ 3 months Exclusion Criteria: * visual/hearing impairment and/or history of reading or written inability/disability sufficient to interfere with MSS training * concurrent participation in another related clinical trial

Locations (1)

Bruyere Research Institute

Ottawa, Ontario, Canada

Outcomes

Primary Outcomes

Adherence to French Memory Support System Intervention

Change from adherence scores from one week after starting treatment (MSS intervention) at treatment end and at 8 weeks after the treatment end. Using an adherence scale from 0 to 10, with 10 being highest and a cut-off score of ≥ 7 points suggesting adherence with the MSS.

Time frame: One week after starting the treatment (MSS intervention), treatment end, and at 8 week follow-up after treatment end.

Secondary Outcomes

Center for Epidemiologic Studies Depression Scale

Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Depression screening scale using Likert scale. Total score of 0-60 points, with higher scores signifying a worse outcome (higher levels of depression).

Time frame: Baseline, treatment end and at 8 week follow-up.

Everyday Cognition questionnaire.

Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Self report measure of performance based instrumental activities of daily living. Total score of 23-92, with higher scores indicating a worse outcome.

Time frame: Baseline and at 8 week follow-up.

Functional Assessment Questionnaire

Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Informant based report of performance of instrumental activities of daily living. Total score of 0-30, with higher scores indicating a worse outcome (higher level of dependence).

Time frame: Baseline and at 8 week follow-up.

Quality of Life in Alzheimer Disease

Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Self report quality of life scale. Total score of 13-52, with higher scores indicating a better outcome (better quality of life).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.